Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
| Condition | Cerebral Infarction |
|---|---|
| Phase | Phase 4 |
| Sponsor | Shionogi |
| Status | Completed |
| Enrollment | 401 participants |
| Interventions | Edaravone, Sodium Ozagrel |
| Start date | Aug 31, 2004 |
| Completion date | Oct 31, 2006 |
| Results posted | Jan 15, 2013 |
Summary
This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
the Rate of Patients With a Modified Rankin Scale Score of 0-1
| Edaravone | 109 participants |
|---|---|
| Ozagrel | 98 participants |
| Edaravone | 46 participants |
| Ozagrel | 39 participants |
| Edaravone | 63 participants |
| Ozagrel | 59 participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Closed-loop Deep Brain Stimulation to Treat Refractory Neuropathic Pain — Prasad Shirvalkar, MD, PhD
- Women's Health Initiative Strong and Healthy Study — Fred Hutchinson Cancer Center
- Zambia Stroke Unit Study — Johns Hopkins University
- Tracking Post-stroke Walking Improvements From the Clinic Into the Home — Western University of Health Sciences
- Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University
- Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke — Shionogi